These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
456 related items for PubMed ID: 19647953
41. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD. Cancer; 2002 Jun 15; 94(12):3083-8. PubMed ID: 12115338 [Abstract] [Full Text] [Related]
42. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Li JM, Wang L, Shen Y, Xia ZG, Chen Y, Chen QS, Chen Y, Zeng XY, You JH, Qian Y, Shen ZX. Ann Hematol; 2007 Sep 15; 86(9):639-45. PubMed ID: 17572895 [Abstract] [Full Text] [Related]
43. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. J Clin Oncol; 2005 Mar 20; 23(9):1984-92. PubMed ID: 15668467 [Abstract] [Full Text] [Related]
44. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. Liu X, Deng T, Guo X, Guo Y, Wang L, Zhang J, Xia Z, Zhang Q, Xue K, Cao J, Shi J, Hong X. Hematology; 2017 Jun 20; 22(5):258-264. PubMed ID: 27884092 [Abstract] [Full Text] [Related]
48. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M. Gan To Kagaku Ryoho; 2005 Dec 20; 32(13):2059-64. PubMed ID: 16352929 [Abstract] [Full Text] [Related]
49. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang. N Engl J Med; 2004 Mar 25; 350(13):1287-95. PubMed ID: 15044639 [Abstract] [Full Text] [Related]
51. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. Kwon J, Kim IH, Kim BH, Kim TM, Heo DS. Int J Radiat Oncol Biol Phys; 2015 May 01; 92(1):91-8. PubMed ID: 25721091 [Abstract] [Full Text] [Related]
52. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T, Hotta T. J Clin Oncol; 2011 Oct 20; 29(30):3990-8. PubMed ID: 21931035 [Abstract] [Full Text] [Related]
54. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation. Hung MH, Yu YB, Huang YC, Liu HT, Hong YC, Hsiao LT, Liu JH, Gau JP, Chiou TJ, Chen PM, Tzeng CH, Liu CY. Ann Hematol; 2012 Dec 20; 91(12):1907-15. PubMed ID: 22885989 [Abstract] [Full Text] [Related]
55. Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-lymphoma. Avilés A, Neri N, Fernández R, Huerta-Guzmán J, Nambo MJ. Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):1227-31. PubMed ID: 22172907 [Abstract] [Full Text] [Related]
57. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. Shin HJ, Yoon DH, Lee HS, Oh SY, Yang DH, Kang HJ, Chong SY, Park Y, Do Y, Lim SN, Jo JC, Lee WS, Chung JS, Consortium for Improving Survival of Lymphoma. Exp Hematol; 2016 Jan 15; 44(1):3-13. PubMed ID: 26325332 [Abstract] [Full Text] [Related]
58. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era. Lu HJ, Huang YC, Liu CY, Hung MH, Hu MH, Wu CY, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Tzeng CH, Yu YB. Ann Hematol; 2013 Nov 15; 92(11):1495-501. PubMed ID: 23712292 [Abstract] [Full Text] [Related]
59. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Colgan JP, Nowakowski GS, Thompson CA, Markovic SN. Leukemia; 2010 Jul 15; 24(7):1343-9. PubMed ID: 20485372 [Abstract] [Full Text] [Related]
60. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma. Skugor ND, Perić Z, Vrhovac R, Radić-Kristo D, Kardum-Skelin I, Jaksić B. Coll Antropol; 2010 Mar 15; 34(1):241-5. PubMed ID: 20432757 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]